Close Menu

NEW YORK – Quantgene and CureMatch said on Wednesday that they have signed a strategic partnership to integrate genomic, cloud, and artificial intelligence technologies and improve precision treatments and long-term outcomes for patients diagnosed with cancer.

The firms also said that they plan to collaborate on advancing genomics and AI-guided oncology tools. 

Santa Monica, California-based Quantgene said its Quantgene Liquid assay profiles cell-free DNA in blood samples from cancer patients to establish their mutational profiles.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.